Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.38 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9487776 | 1.00 | MAPT (0.38) | MAPTLMNASLC29A1DNM1KMT2A | |
| SCHEMBL10912436 | 1.00 | MAPT (0.38) | MAPTLMNASLC29A1DNM1KMT2A | |
| SCHEMBL3940882 | 1.00 | MAPT (0.38) | MAPTLMNASLC29A1DNM1KMT2A | |
| SCHEMBL26655864 | 0.96 | MAPT (0.40) | MAPTLMNASLC29A1DNM1KMT2A | |
| SCHEMBL13299491 | 0.96 | MAPT (0.40) | MAPTLMNASLC29A1DNM1KMT2A | |
| SCHEMBL10803771 | 0.92 | MAPT (0.40) | MAPTLMNASLC29A1KMT2ASMN1; SMN2 | |
| SCHEMBL26771664 | 0.88 | DNM1 (0.36) | MAPTLMNASLC29A1DNM1KMT2A | |
| SCHEMBL13299499 | 0.88 | DNM1 (0.36) | MAPTLMNASLC29A1DNM1KMT2A | |
| SCHEMBL13299493 | 0.88 | DNM1 (0.36) | MAPTLMNASLC29A1DNM1KMT2A | |
| SCHEMBL523376 | 0.88 | MAPT (0.42) | MAPTLMNASLC29A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11299504-B2 | Process for preparing a triazine-based precursor, the precursor prepared thereby, a method for producing a micro-particulate complex using the precursor, and the micro-particulate complex produced thereby | NATIONAL CHI NAN UNIVERSITY (TW) | 2022-04-12 | — | — | US | disclosed |
| CN-109400543-B | Triazine precursor, method for preparing triazine precursor and application of triazine precursor | 暨南国际大学 | 2022-03-01 | — | — | CN | disclosed |
| US-20200369687-A1 | Process for Preparing a Triazine-Based Precursor, the Precursor Prepared Thereby, a Method for Producing a Micro-Particulate Complex Using the Precursor, and the Micro-Particulate Complex Produced Thereby | NATIONAL CHI NAN UNIVERSITY (TW) | 2020-11-26 | — | — | US | disclosed |
| US-20190055270-A1 | Process for Preparing a Triazine-Based Precursor, the Precursor Prepared Thereby, a Method for Producing a Micro-Particulate Complex Using the Precursor, and the Micro-Particulate Complex Produced Thereby | NATIONAL CHI NAN UNIVERSITY (TW) | 2019-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055270-A1 | Process for Preparing a Triazine-Based Precursor, the Precursor Prepared Thereby, a Method for Producing a Micro-Particulate Complex Using the Precursor, and the Micro-Particulate Complex Produced Thereby | SSRP1, RRP15, SUB1 | MAPT 1446/4885LMNA 3011/4885SLC29A1 4530/4885 |
| US-11299504-B2 | Process for preparing a triazine-based precursor, the precursor prepared thereby, a method for producing a micro-particulate complex using the precursor, and the micro-particulate complex produced thereby | SSRP1, RRP15, SUB1 | MAPT 1446/4885LMNA 3011/4885SLC29A1 4530/4885 |
| US-20200369687-A1 | Process for Preparing a Triazine-Based Precursor, the Precursor Prepared Thereby, a Method for Producing a Micro-Particulate Complex Using the Precursor, and the Micro-Particulate Complex Produced Thereby | SSRP1, RRP15, SUB1 | MAPT 1446/4885LMNA 3011/4885SLC29A1 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.